Does the media prefer ACAD or BBIO?

In the previous week, ACADIA Pharmaceuticals had 25 more articles in the media than BridgeBio Pharma. MarketBeat recorded 33 mentions for ACADIA Pharmaceuticals and 8 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.87 beat ACADIA Pharmaceuticals' score of 0.80 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 11 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ACAD or ASND?

In the previous week, ACADIA Pharmaceuticals had 28 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 33 mentions for ACADIA Pharmaceuticals and 5 mentions for Ascendis Pharma A/S. ACADIA Pharmaceuticals' average media sentiment score of 0.80 beat Ascendis Pharma A/S's score of 0.67 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 11 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to EXEL or ACAD?

In the previous week, Exelixis had 9 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 42 mentions for Exelixis and 33 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.80 beat Exelixis' score of 0.30 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 11 Very Positive mention(s) 2 Positive mention(s) 12 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 11 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ACAD or ARWR?

In the previous week, ACADIA Pharmaceuticals had 2 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 33 mentions for ACADIA Pharmaceuticals and 31 mentions for Arrowhead Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.80 beat Arrowhead Pharmaceuticals' score of 0.06 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 11 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 9 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor BMRN or ACAD?

In the previous week, ACADIA Pharmaceuticals had 5 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 33 mentions for ACADIA Pharmaceuticals and 28 mentions for BioMarin Pharmaceutical. ACADIA Pharmaceuticals' average media sentiment score of 0.80 beat BioMarin Pharmaceutical's score of 0.77 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 9 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 11 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ACADIA Pharmaceuticals (ACAD) Competitors

$29.40 +0.19 (+0.65%)

As of 11:35 AM Eastern

Compare

ACAD vs. BBIO, ASND, EXEL, ARWR, and BMRN

Should you buy ACADIA Pharmaceuticals stock or one of its competitors? MarketBeat compares ACADIA Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ACADIA Pharmaceuticals include BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), Exelixis (EXEL), Arrowhead Pharmaceuticals (ARWR), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "biotechnology" industry.

How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

ACADIA Pharmaceuticals has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

ACADIA Pharmaceuticals presently has a consensus target price of $33.44, indicating a potential upside of 13.75%. BridgeBio Pharma has a consensus target price of $97.33, indicating a potential upside of 14.16%. Given BridgeBio Pharma's higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.82

ACADIA Pharmaceuticals has a net margin of 33.42% compared to BridgeBio Pharma's net margin of -124.42%. ACADIA Pharmaceuticals' return on equity of 9.03% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
BridgeBio Pharma	-124.42%	N/A	-65.81%

ACADIA Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.73	$391M	$2.22	13.24
BridgeBio Pharma	$502.08M	33.20	-$724.93M	-$3.74	N/A

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, ACADIA Pharmaceuticals had 25 more articles in the media than BridgeBio Pharma. MarketBeat recorded 33 mentions for ACADIA Pharmaceuticals and 8 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.87 beat ACADIA Pharmaceuticals' score of 0.80 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	11 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ACADIA Pharmaceuticals beats BridgeBio Pharma on 10 of the 16 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to Ascendis Pharma A/S?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Ascendis Pharma A/S has a net margin of 57.87% compared to ACADIA Pharmaceuticals' net margin of 33.42%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

ACADIA Pharmaceuticals has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, ACADIA Pharmaceuticals had 28 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 33 mentions for ACADIA Pharmaceuticals and 5 mentions for Ascendis Pharma A/S. ACADIA Pharmaceuticals' average media sentiment score of 0.80 beat Ascendis Pharma A/S's score of 0.67 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	11 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.73	$391M	$2.22	13.24
Ascendis Pharma A/S	$814.57M	19.49	-$258M	$8.67	29.35

ACADIA Pharmaceuticals currently has a consensus target price of $33.44, indicating a potential upside of 13.75%. Ascendis Pharma A/S has a consensus target price of $296.12, indicating a potential upside of 16.35%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.06

Summary

Ascendis Pharma A/S beats ACADIA Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to Exelixis?

Exelixis (NASDAQ:EXEL) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

Exelixis has a net margin of 35.33% compared to ACADIA Pharmaceuticals' net margin of 33.42%. Exelixis' return on equity of 42.17% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

Exelixis has higher revenue and earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.75	$782.57M	$3.18	16.70
ACADIA Pharmaceuticals	$1.07B	4.73	$391M	$2.22	13.24

Exelixis has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

85.3% of Exelixis shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Exelixis had 9 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 42 mentions for Exelixis and 33 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.80 beat Exelixis' score of 0.30 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	11 Very Positive mention(s)	2 Positive mention(s)	12 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	11 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis currently has a consensus price target of $49.79, suggesting a potential downside of 6.26%. ACADIA Pharmaceuticals has a consensus price target of $33.44, suggesting a potential upside of 13.75%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	10 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.26
ACADIA Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

Exelixis beats ACADIA Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to Arrowhead Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

In the previous week, ACADIA Pharmaceuticals had 2 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 33 mentions for ACADIA Pharmaceuticals and 31 mentions for Arrowhead Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.80 beat Arrowhead Pharmaceuticals' score of 0.06 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	11 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	9 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

ACADIA Pharmaceuticals presently has a consensus price target of $33.44, indicating a potential upside of 13.75%. Arrowhead Pharmaceuticals has a consensus price target of $97.33, indicating a potential upside of 10.57%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe ACADIA Pharmaceuticals is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

ACADIA Pharmaceuticals has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

ACADIA Pharmaceuticals has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.73	$391M	$2.22	13.24
Arrowhead Pharmaceuticals	$669.50M	18.52	-$1.63M	-$2.25	N/A

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

ACADIA Pharmaceuticals beats Arrowhead Pharmaceuticals on 14 of the 16 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

In the previous week, ACADIA Pharmaceuticals had 5 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 33 mentions for ACADIA Pharmaceuticals and 28 mentions for BioMarin Pharmaceutical. ACADIA Pharmaceuticals' average media sentiment score of 0.80 beat BioMarin Pharmaceutical's score of 0.77 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	9 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	11 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals has lower revenue, but higher earnings than BioMarin Pharmaceutical. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.94	$348.90M	$0.37	177.34
ACADIA Pharmaceuticals	$1.07B	4.73	$391M	$2.22	13.24

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to BioMarin Pharmaceutical's net margin of 2.14%. ACADIA Pharmaceuticals' return on equity of 9.03% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

BioMarin Pharmaceutical has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market.

BioMarin Pharmaceutical currently has a consensus target price of $88.00, indicating a potential upside of 34.11%. ACADIA Pharmaceuticals has a consensus target price of $33.44, indicating a potential upside of 13.75%. Given BioMarin Pharmaceutical's higher probable upside, equities analysts clearly believe BioMarin Pharmaceutical is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.71
ACADIA Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

ACADIA Pharmaceuticals beats BioMarin Pharmaceutical on 11 of the 17 factors compared between the two stocks.

Get ACADIA Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACAD vs. The Competition

Export

Metric	ACADIA Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.07B	$3.71B	$7.03B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	13.27	9.06	269.91	24.87
Price / Sales	4.73	1,278.42	654.69	108.21
Price / Cash	32.93	44.95	28.89	37.44
Price / Book	4.06	17.97	11.40	6.45
Net Income	$391M	-$13.25M	$3.45B	$347.50M
7 Day Performance	14.80%	5.58%	3.66%	3.77%
1 Month Performance	12.13%	-1.60%	-0.49%	-0.40%
1 Year Performance	19.51%	61.32%	77.51%	23.55%

ACADIA Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACAD ACADIA Pharmaceuticals	4.3226 of 5 stars	$29.40 +0.7%	$33.44 +13.7%	+18.7%	$5.07B	$1.07B	13.27	510	Earnings Report Analyst Upgrade Insider Trade Analyst Revision
BBIO BridgeBio Pharma	2.629 of 5 stars	$79.96 -0.2%	$95.21 +19.1%	+81.4%	$15.66B	$502.08M	N/A	400
ASND Ascendis Pharma A/S	4.6781 of 5 stars	$243.45 -0.2%	$296.72 +21.9%	+33.4%	$15.21B	$814.57M	28.08	1,189	Upcoming Earnings
EXEL Exelixis	2.2323 of 5 stars	$55.06 +3.8%	$49.50 -10.1%	+43.3%	$13.33B	$2.32B	18.29	1,077	Positive News Earnings Report Analyst Downgrade
ARWR Arrowhead Pharmaceuticals	1.8269 of 5 stars	$86.01 +1.6%	$96.92 +12.7%	+433.8%	$11.92B	$622.01M	N/A	400	Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACAD) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ACADIA Pharmaceuticals (ACAD) Competitors

ACAD vs. BBIO, ASND, EXEL, ARWR, and BMRN

How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does ACADIA Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does ACADIA Pharmaceuticals compare to Exelixis?

Summary

How does ACADIA Pharmaceuticals compare to Arrowhead Pharmaceuticals?

Summary

How does ACADIA Pharmaceuticals compare to BioMarin Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACAD vs. The Competition

ACADIA Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ACADIA Pharmaceuticals (ACAD) Competitors

ACAD vs. BBIO, ASND, EXEL, ARWR, and BMRN

How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?

Which has more volatility & risk, ACAD or BBIO?

Do analysts rate ACAD or BBIO?

Is ACAD or BBIO more profitable?

Which has stronger earnings and valuation, ACAD or BBIO?

Do institutionals & insiders believe in ACAD or BBIO?

Does the media prefer ACAD or BBIO?

Summary

How does ACADIA Pharmaceuticals compare to Ascendis Pharma A/S?

Is ACAD or ASND more profitable?

Which has more risk and volatility, ACAD or ASND?

Do insiders & institutionals believe in ACAD or ASND?

Does the media prefer ACAD or ASND?

Which has better valuation and earnings, ACAD or ASND?

Do analysts rate ACAD or ASND?

Summary

How does ACADIA Pharmaceuticals compare to Exelixis?

Is EXEL or ACAD more profitable?

Which has stronger earnings and valuation, EXEL or ACAD?

Which has more volatility and risk, EXEL or ACAD?

Do insiders & institutionals believe in EXEL or ACAD?

Does the media refer more to EXEL or ACAD?

Do analysts rate EXEL or ACAD?

Summary

How does ACADIA Pharmaceuticals compare to Arrowhead Pharmaceuticals?

Is ACAD or ARWR more profitable?

Does the media prefer ACAD or ARWR?

Do analysts prefer ACAD or ARWR?

Which has more risk & volatility, ACAD or ARWR?

Which has preferable valuation and earnings, ACAD or ARWR?

Do institutionals & insiders believe in ACAD or ARWR?

Summary

How does ACADIA Pharmaceuticals compare to BioMarin Pharmaceutical?

Does the media favor BMRN or ACAD?

Which has better earnings and valuation, BMRN or ACAD?

Do institutionals and insiders believe in BMRN or ACAD?

Is BMRN or ACAD more profitable?

Which has more volatility and risk, BMRN or ACAD?

Do analysts rate BMRN or ACAD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACAD vs. The Competition

ACADIA Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools